Stockholders' Equity (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2022

Dec. 31, 2021

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Summary of Stock-Based Compensation Expense Recognized

The table below shows stock-based compensation expense recognized from both the 2008 Plan and 2016 Plan in the statements of operations for the years ended December 31:

	2021		2020
Cost of revenues	$	693	$	27
Research and development		233		7
Sales, general and administrative		1,547		48
	$	2,473	$	82

Summary of Weighted-Average Assumptions for Options Granted

The weighted-average assumptions for options granted to calculate the grant date fair value of grants issued under the 2008 Plan were as follows for the years ended December 31:

	2021			2020
Dividend yield		—			—
Expected volatility		52.18	%		50.27	%
Expected term (in years)		5.01			5.75
Risk-free rate		1.19	%		0.14	%

The weighted-average assumptions for options granted to calculate the grant date fair value of grants issued under the 2016 Plan were as follows for the year ended December 31, 2021:

	2021
Dividend yield		—
Expected volatility		51.75	%
Expected term (in years)		5.92
Risk-free rate		1.07	%

2008 Stock Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Summary of Option Activity

A summary of option activity under the 2008 Plan for the years ended December 31, 2021 and 2020 and is as follows:

	Shares Available for Grant			Outstanding Stock Options			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (Years)		Average Intrinsic Value
Balance as of January 1, 2020		1,927,978			8,558,849		$	0.48		3.82	$	11,137
Options granted		(1,393,713	)		1,393,713			1.73		—		—
Options exercised		—			(3,000	)		0.03		—		1
Options expired		1,475,713			(1,475,713	)		0.10		—		—
Balance as of December 31, 2020		2,009,978			8,473,849			0.75		4.52		14,068
Options granted		(3,609,610	)		3,609,610			2.43		—		—
Options exercised		—			(51,291	)		0.28		—		28
Options expired		1,975,178			(1,975,178	)		0.28		—		—
Balance as of December 31, 2021		375,546			10,056,990		$	1.49		6.53	$	10,995
Options vested and exercisable as of December 31, 2021					9,327,678		$	1.46		6.35	$	10,401
Options vested and expected to vest as of December 31, 2021					10,056,990		$	1.49		6.53	$	10,995

2016 Equity Incentive Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Summary of Option Activity

A summary of option activity under the 2016 Plan for the years ended December 31, 2021 and 2020 is as follows:

	Shares Available for Grant			Outstanding Stock Options			Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (Years)		Average Intrinsic Value
Balance as of January 1, 2020		1,124,473			6,000,484		$	0.10		4.90	$	2,104
Options granted		—			—			—		—		—
Options exercised		—			(72,795	)		0.05		—		29
Options expired		196,544			(196,544	)		0.35		—		—
Balance as of December 31, 2020		1,321,017			5,731,145			0.09		3.79		9,654
Shares Authorized		9,099,380			—			—		—		—
Options granted		(4,707,235	)		4,707,235			1.77		—		—
Options exercised		—			(29,118	)		0.05		—		54
Options expired		36,397			(36,397	)		0.21		—		—
Balance as of December 31, 2021		5,749,559			10,372,865		$	0.85		5.86	$	16,208
Options vested and exercisable as of December 31, 2021					6,348,921		$	0.28		3.56	$	13,542
Options vested and expected to vest as of December 31, 2021					10,372,865		$	0.85		5.86	$	16,208

(1) Number of shares and exercise price disclosed are restated for the retroactive application to reflect the effect of the Exchange Ratio established in the Business Combination in Note 1.

2008 and 2016 Employee Stock Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Summary of Stock-Based Compensation Expense Recognized

The table below shows stock-based compensation expense recognized for both the 2008 and 2016 Plans for the three and nine months ended September 30, 2022 and 2021:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Cost of revenue	$	125	$	86	$	357	$	250
Research and development		6		7		20		11
Selling, general and administrative		646		230		1,746		441
Total stock-based compensation expense	$	777	$	323	$	2,123	$	702